Adrian Rawcliffe
Directeur Général chez ADAPTIMMUNE THERAPEUTICS PLC
Fortune : 330 238 $ au 31/05/2024
Profil
Mr. Adrian Rawcliffe is an Independent Director at Wave Life Sciences Ltd., a Chief Executive Officer & Director at Adaptimmune Therapeutics Plc and a Chief Financial Officer at Human Genome Sciences, Inc. He is on the Board of Directors at Wave Life Sciences Ltd., Adaptimmune Therapeutics Plc, Morphotek, Inc. and Wave Life Sciences USA, Inc. Mr. Rawcliffe was previously employed as a Managing Partner by SR One Ltd., a Senior Vice President-Finance by GlaxoSmithKline Plc, a Principal by AlgoRx Pharmaceuticals, Inc., and a Vice President by GlaxoSmithKline Biologicals SA. He received his undergraduate degree from the University of Durham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 1 594 836 ( 0,28% ) | 300 419 $ | 31/05/2024 | |
| 12/01/2024 | 26 388 ( 0,01% ) | 29 818 $ | 31/05/2024 | |
WAVE LIFE SCIENCES LTD.
-.--% | 27/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Adrian Rawcliffe
| Sociétés | Poste | Début |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Directeur Général | 01/09/2019 |
| WAVE LIFE SCIENCES LTD. | Directeur/Membre du Conseil | 01/02/2017 |
Morphotek, Inc.
 Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Directeur/Membre du Conseil | - |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Directeur Financier/CFO | 30/07/2012 |
Wave Life Sciences USA, Inc.
 Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno. | Directeur/Membre du Conseil | - |
Adaptimmune Ltd.
 Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Adrian Rawcliffe
| Sociétés | Poste | Fin |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01/01/2015 |
AlgoRx Pharmaceuticals, Inc.
 AlgoRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AlgoRx Pharmaceuticals, Inc. was a pharmaceutical company. The company developed and commercialized drugs for pain management. The company was founded in 2001 and was hedquartered in Secaucus, NJ. | Corporate Officer/Principal | 18/02/2009 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | President | 01/01/2006 |
| ░░░░░░░░░░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Adrian Rawcliffe
| University of Durham | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| WAVE LIFE SCIENCES LTD. | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 7 |
|---|---|
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Morphotek, Inc.
Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Commercial Services |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Health Technology |
AlgoRx Pharmaceuticals, Inc.
AlgoRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AlgoRx Pharmaceuticals, Inc. was a pharmaceutical company. The company developed and commercialized drugs for pain management. The company was founded in 2001 and was hedquartered in Secaucus, NJ. | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Wave Life Sciences USA, Inc.
Wave Life Sciences USA, Inc. Electric UtilitiesUtilities Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno. | Utilities |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
